BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

BioAtla, a clinical-stage biotechnology company, announced its participation in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco from January 9-12, 2023. The company will host a fireside chat and conduct one-on-one investor meetings on January 10, 2023, at 3:00 p.m. PST. BioAtla focuses on developing Conditionally Active Biologic (CAB) therapeutics for solid tumors. The firm boasts extensive patent coverage and currently has two first-in-class CAB programs in Phase 2 clinical testing, targeting AXL and ROR2.

SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the 41^st Annual J.P. Morgan Healthcare Conference, to be held in San Francisco, CA January 9-12, 2023.

Format: Fireside chat and scheduled one-on-one investor meetings
Date: Tuesday, January 10, 2023
Time: 3:00 p.m. PST
Location: San Francisco, CA
Webcast Link: Click Here

About BioAtla, Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal antibody and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with more than 600 patents, more than 350 of which are issued. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing in the United States, mecbotamab vedotin, BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 1 stage CAB-CTLA-4 antibody, BA3071, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. To learn more about BioAtla, Inc. visit www.bioatla.com.

Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945

External Contact:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com

FAQ

What is BioAtla's participation in the J.P. Morgan Healthcare Conference?

BioAtla will participate in a fireside chat and hold one-on-one investor meetings on January 10, 2023, during the J.P. Morgan Healthcare Conference.

When and where is the J.P. Morgan Healthcare Conference taking place?

The conference will take place in San Francisco, CA from January 9-12, 2023.

What are BioAtla's key products currently in clinical testing?

BioAtla has two first-in-class CAB programs in Phase 2 testing: mecbotamab vedotin (BA3011) and ozuriftamab vedotin (BA3021).

What is the technology behind BioAtla's products?

BioAtla develops therapeutics using its proprietary Conditionally Active Biologic (CAB) technology, which aims for selective targeting and reduced toxicity.

How many patents does BioAtla hold for its CAB technology?

BioAtla has more than 600 patents related to its CAB technology, over 350 of which are issued.